Navigation Links
Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
Date:5/9/2008

ir. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any fut
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
2. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
3. Alseres Pharmaceuticals, Inc. Raises $5 Million
4. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
5. Vion Pharmaceuticals to Appeal Nasdaq Delisting
6. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
7. ISTA Pharmaceuticals to Present at the Bank of America 2008 Health Care Conference
8. ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
9. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... The Linda Hall Library ... of a comet, the IceCube observatory at the South Pole, and the interior of ... Fall Lecture Series for the world's foremost independently funded research library devoted to science, ...
(Date:9/3/2015)... ... September 03, 2015 , ... B. E. Smith, ... retained to lead a national chief executive officer recruitment for Melissa ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare ...
(Date:9/3/2015)... CANADA (PRWEB) , ... September 03, 2015 , ... ... today announced that it will be spotlighting its award-winning print and artwork inspection solutions, ... Vision team September 16 and 17 at the Olympia London, booth #F33 , Be ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... DiabetesSisters is pleased to announce the additional of Carol Wysham, MD, to their ... board members Diana Karczmarczyk, Donna Rice, David Warren, Matt Stella, Tricia Cedotal, Andrea ...
(Date:9/3/2015)... ... 03, 2015 , ... ProScrub is a set of automated tools that allow ... custom speed effects without the use of keyframes. Utilize ProScrub's powerful sliders to ... are perfect complements to energetic video productions. ProScrub is a Final Cut ...
Breaking Medicine News(10 mins):Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 2Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 3Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 4Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 5Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 3Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2
... (About Euro 46 M),Frutarom Establishes its Position as One of the 10 Largest ... ... Frutarom Continues to Implement Rapid Growth Strategy, HAIFA, Israel, October ... it has signed an agreement to acquire 100% of the share capital of ...
... (October 15, 2007) Patients have on average a ... top-rated hospitals compared with the lowest-rated hospitals across 18 ... Hospital Quality in America Study, issued today by HealthGrades, ... wide variation in the quality of care between the ...
... A new study by Rhode Island Hospital and Brown University ... surgery did not receive the initial psychiatric clearance for the ... of decisions to clear candidates for surgery, and the largest ... and detail the reasons for exclusion. It was published in ...
... created an easy-to-produce material from the stuff of ... bend light in the opposite direction from all ... to significant advances in many areas, including high-speed ... A Princeton-led research team has created an easy-to-produce ...
... other vital organs is critical for survival, experts say, ... flow to the brain and other vital organs is ... emphasize chest compressions over rescue breathing, particularly for heart ... is just two breaths per every 30 chest compressions. ...
... in Support of National Breast ... Cure, DALLAS, Oct. 13 NASCAR drivers Bobby ... Cure at today,s Bank of,America 500 race at Lowe,s ... ) Bobby Labonte,s #43, sponsored by General Mills, ...
Cached Medicine News:Health News:Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors 2Health News:Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors 3Health News:Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors 4Health News:Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors 5Health News:Mortality rates 71 percent lower at top-rated hospitals: HealthGrades 2008 hospital-quality study 2Health News:Mortality rates 71 percent lower at top-rated hospitals: HealthGrades 2008 hospital-quality study 3Health News:1 in 5 bariatric surgery candidates not psychologically cleared for surgery 2Health News:Novel semiconductor structure bends light 'wrong' way -- the right direction for many applications 2Health News:Novel semiconductor structure bends light 'wrong' way -- the right direction for many applications 3Health News:Chest Compressions Key to Revised CPR Guidelines 2Health News:Chest Compressions Key to Revised CPR Guidelines 3Health News:General Mills' #43, M&M's #38 Driving Passionately Pink for the Cure at Lowe's Motor Speedway NASCAR Race 2
(Date:9/3/2015)... SEATTLE , Sept. 3, 2015  Omeros Corporation ... filed patent infringement lawsuits against Par Pharmaceutical, Inc. and ... the U.S. District Court for the District of ... District Court for the District of Delaware ... Act for Par,s infringement of three Omeros patents, U.S. ...
(Date:9/3/2015)... Sept. 3, 2015 Research and Markets ... the "Investigation Report on China Tamsulosin Market, ... Compared with other a1- adrenergic receptor blockers, ... and lower risk of urinary tract infections and ... its debut in 1993 in Japan ...
(Date:9/3/2015)... Pharma major Lupin Limited ... (Lupin) has launched its Duloxetine 40 mg Delayed-Release ... generic Duloxetine formulation to become available in 40 ... this new strength to market, as it adds ... flexibility of treatment.      (Photo: ...
Breaking Medicine Technology:Omeros Files Infringement Suits Against Par 2Omeros Files Infringement Suits Against Par 3Omeros Files Infringement Suits Against Par 4China Tamsulosin Market Investigation Report 2015 2Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US 2Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US 3Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US 4
... 30, 2011 Company remains committed to ... R&D pipeline boasts 70 potential medicines in clinical development, including ... at least ten potential new medicines in Phase III by the ... therapeutic areas such as neuroscience, diabetes and oncology, as well as ...
... June 29, 2011 OnCore® Software ... Toolkit works with any eIRB system, including commercial and homegrown ... direction between Clinical Trials Management System (CTMS) and eIRB system. ... timely access to both clinical and regulatory data. ...
Cached Medicine Technology:Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 2Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 3Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 4Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 5Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 6Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 7Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 8Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 9Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 10Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 11Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 12Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 13Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 14Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 15Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 16Forte Research Systems Opens Their OnCore Software Developer Toolkit for Use With Any eIRB System 2Forte Research Systems Opens Their OnCore Software Developer Toolkit for Use With Any eIRB System 3
... Addressing the key clinical and economic issues ... System is designed to maximize tension control ... The system combines efficient instrumentation with a ... Grip system is indicated for general orthopaedic ...
... The Minimally Invasive Hip Instruments ... THA through a mini-incision using ... set of instruments helps reduce ... invasive THA by optimizing exposure ...
... The Inteq TFCC ... facilitates suturing of the ... the dorsal capsule when ... The Inteq system should ...
... Series I Small Joint ... features a complete line ... instruments specifically designed for ... are available in a ...
Medicine Products: